Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Biologics License Application for Subcutaneous Formulation of "LEQEMBI®" for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
FDA Accepts LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
FDA Accepts LEQEMBI® IQLIKTM Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® for Spinal Muscular Atrophy
Biologics License Application for Subcutaneous Formulation of "LEQEMBI®" for the Treatment of Early Alzheimer's Disease Accepted in China
The Journal of the American Medical Association Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
"LEQEMBI®" for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society Annual Meeting
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease Conference 2025
Domestic Metals Completes Surface IP Geophysical Survey at Smart Creek and Announces Amendment to Warrant Terms of Unit Private Placement
RETRANSMISSION: West High Yield Resources Ltd. Signs Definitive Forward Sales Agreement to Sell Magnesium Ore from Its Record Ridge Project
Anteros Metals Reports Assay Results from RM26-01 and Provides Exploration Update at the Seagull Critical Minerals Project, Ontario
